• 1
    Brawley O. Prostate carcinoma incidence and patient mortality: the effects of screening and early detection. Cancer 1997; 80: 185763
  • 2
    Farkas A, Schneider D, Perrotti M, Cummings KB, Ward WS. National trends in the epidemiology of prostate cancer, 1973–94: evidence for the effectiveness of prostate-specific antigen screening. Urology 1998; 52: 4449
  • 3
    Garnick MB. Hormonal therapy in the management of prostate cancer: from Huggins to the present. Urology 1997; 49 (Suppl. 3A): 515
  • 4
    Chodak G, Keane T, Klotz L; The Hormone Therapy Study Group. Critical evaluation of hormonal therapy for carcinoma of the prostate. Urology 2002; 60: 2018
  • 5
    Herr HW, O’Sullivan M. Quality of life of asymptomatic men with nonmetastatic prostate cancer on androgen deprivation therapy. J Urol 2000; 163: 17436
  • 6
    Lubeck DP, Grossfeld GD, Carroll PR. The effect of androgen deprivation therapy on health-related quality of life in men with prostate cancer. Urology 2001; 58 (Suppl. 2): 94100
  • 7
    Fowler FJ Jr, McNaughton Collins M, Walker Corkery E, Elliott DB, Barry MJ. The impact of androgen deprivation on quality of life after radical prostatectomy for prostate carcinoma. Cancer 2002; 95: 28795
  • 8
    Mariani AJ, Glover M, Arita S. Medical versus surgical androgen suppression therapy for prostate cancer: a 10-year longitudinal cost study. J Urol 2001; 165: 1047
  • 9
    Catalona WJ. Screening for prostate cancer: enthusiasm. Urology 1993; 42: 1135
  • 10
    Andriole GL. The case for prostate cancer screening. Semin Urol 1993; 11: 503
  • 11
    Coley CM, Barry MJ, Fleming C, Fahs MC, Mulley AG. Early detection of prostate cancer. Part II: Estimating the risks, benefits and costs. American College of Physicians. Ann Intern Med 1997; 126: 46879
  • 12
    Tombal B, De Visccher L, Cosyns J et al. Assessing the risk of unsuspected prostate cancer in patients with benign prostatic hypertrophy: a 13-year retrospective study of the incidence and natural history of T1a-T1b prostate cancers. BJU Int 1999; 84: 101520
  • 13
    Zigeuner RE, Lipsky K, Riedler I et al. Did the rate of incidental prostate cancer change in the era of PSA testing? A retrospective study of 1127 patients. Urology 2003; 62: 4515
  • 14
    Schroder FH, Van Der Maas P, Beemsterboer P et al. Evaluation of the digital rectal examination as a screening test for prostate cancer. Rotterdam section of the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 1998; 90: 181723
  • 15
    Wennberg J, Cooper M. The Dartmouth Atlas of Health Care in the United States. Chicago, IL: American Hospital Publishing, Inc., 1998
  • 16
    Ries L, Eisner M, Kosary C et al. SEER Cancer Statistics Review 1975–2001. Bethesda, MD: National Cancer Institute, 2004
  • 17
    Meng MV, Grossfeld GD, Sadetsky N, Mehta SS, Lubeck DP, Carroll PR. Contemporary patterns of androgen deprivation therapy use for newly diagnosed prostate cancer. Urology 2002; 60 (Suppl. 3A): 712
  • 18
    Cooperberg MR, Grossfeld GD, Lubeck DP, Carroll PR. National practice patterns and time trends in androgen ablation for prostate cancer. J Natl Cancer Inst 2003; 95: 9819
  • 19
    Zietman A, Thakral H, Skowronski U, Shipley W. Freedom from castration: an alternative end point for men with localized prostate cancer treated by external beam radiation therapy. Int J Radiat Oncol Biol Phys 2002; 53: 11529
  • 20
    Mehta SS, Lubeck DP, Sadetsky N, Pasta DJ, Carroll PR. Patterns of secondary cancer treatment for biochemical failure following radical prostatectomy: data from CaPSURE. J Urol 2004; 171: 2159
  • 21
    Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999; 281: 15917
  • 22
    Potosky AL, Knopf K, Clegg LX et al. Quality-of-life outcomes after primary androgen deprivation therapy: results from the Prostate Cancer Outcomes Study. J Clin Oncol 2001; 19: 37507
  • 23
    The Medical Research Council Prostate Cancer Working Party Investigators Group. Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council trial. Br J Urol 1997; 79: 23546
  • 24
    Messing EM, Manola J, Sarosdy M, Wilding G, Crawford ED, Trump D. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 1999; 341: 17818
  • 25
    Bolla M, Collette L, Blank L et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 2002; 360: 1036
  • 26
    D’Amico AV, Manola J, Loffredo M, Renshaw AA, DellaCroce A, Kantoff PW. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA 2004; 292: 8217
  • 27
    Aronson A, Seidenfeld J, Samson D et al. Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostate cancer. Rockville, MD: Agency for Health Care Policy and Research, 1999
  • 28
    Oottamasathien S, Crawford ED. Should routine screening for prostate-specific antigen be recommended? Arch Intern Med 2003; 163: 6612
  • 29
    Oliver SS, Gunnell D, Donovan JL. Comparison of trends in prostate-cancer mortality in England and Wales and the USA. Lancet 2000; 355: 17889
  • 30
    Lu-Yao G, Albertsen PC, Stanford JL, Stukel TA, Walker-Corkery ES, Barry MJ. Natural experiment examining impact of aggressive screening and treatment on prostate cancer mortality in two fixed cohorts from Seattle area and Connecticut. BMJ 2002; 325: 7405
  • 31
    Albertsen PC. The prostate cancer conundrum. J Natl Cancer Inst 2003; 95: 9301
  • 32
    Merrill RM, Weed DL, Feuer EJ. The lifetime risk of developing prostate cancer in white and black men. Cancer Epidemiol Biomarkers Prev 1997; 6: 7638
  • 33
    Sirovich BE, Schwartz LM, Woloshin S. Screening men for prostate and colorectal cancer in the United States: does practice reflect the evidence? JAMA 2003; 289: 141420
  • 34
    Ross LE, Coates RJ, Breen N, Uhler RJ, Potosky AL, Blackman D. Prostate-specific antigen test use reported in the 2000 National Health Interview Survey. Prev Med 2004; 38: 73244